vertex journavx suzetrigine - Search News

FDA Approves 1st-in-Class Non-Opioid Pain Drug Journavx

Scientific American · 3d

What Is Journavx, the New Opioid-Free Painkiller from Vertex?

The nonaddictive painkiller suzetrigine (Journavx) is as effective for acute pain as a common opioid treatment

The Motley Fool on MSN · 1d

Is Vertex Pharmaceuticals a Buy Now That the FDA Approved Its New Pain Drug?

Lately, one of America's leading pharmaceutical companies can't catch a break from Wall Street. Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) are down about 9% from a peak the stock set in November,

FDA Approves Vertex’s Journavx as First New Pain Drug in Decades

The greenlight for Journavx (suzetrigine), which comes on the heels of a $7.4 billion opioid settlement, could spark momentum in the fledgling non-opioid pain space.

Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has ...

2d

Vertex: Maintaining Buy Despite Tempered Expectations For Journavx In Pain

Vertex's Journavx got FDA approval for acute pain but faces adoption challenges. Click here to read more about VRTX stock and ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results